Drugs / NEPIDERMIN
NEPIDERMIN
also known as
rhEGF · epidermal growth factor · EGF · recombinant human Epidermal Growth Factor · EGF-genesis · Nepidermina · Nepidermine
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04886726 | Dec 2021 → Nov 2028 expected | graft versus host disease | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 1 | NCT04375618 | Oct 2019 → Oct 2020 | periodontitis | SVS Institute of Dental Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT05219461 | Mar → Nov 2019 | dry eye syndrome | Daewoong Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01566578 | Apr → Nov 2012 | psoriasis | Ennar Pharmaceuticals AF | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01593995 | May 2012 → Dec 2013 | malignant pancreatic neoplasm, non-small cell lung carcinoma | Dong-A University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01553708 | Dec 2011 → May 2012 | — | Chulalongkorn University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02554851 | Jan 2017 → Dec 2019 | ulcer of lower limbs | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
| Phase 3 | NCT01629199 | Oct 2010 → Sep 2012 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT01099891 | Mar 2010 → Dec 2015 | stomatitis | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05724589 | Jan 2023 → Jun 2024 | premature aging syndrome | Institute of Dermatology, Thailand | Completed | No outcome recorded |
| — | NCT04704245 | Jul 2017 → Sep 2018 | hyperpigmentation of the skin, lipodystrophy due to peptidic growth factors deficiency | Hallym University Kangnam Sacred Heart Hospital | Completed | No outcome recorded |
| — | NCT03051880 | Nov 2016 → Dec 2017 | — | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT03047863 | Nov 2016 → Aug 2017 | — | The Catholic University of Korea | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04235296 Comparator | Nov 2019 → Dec 2020 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00845819 Comparator | Feb 2009 → Oct 2014 | chemotherapy-induced oral mucositis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02284139 Comparator | Apr 2015 → Dec 2016 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Dong-A University Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06044974 Comparator | Jan → Aug 2023 | temporomandibular joint disorder | Alexandria University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05335720 Comparator | Jul 2019 → Mar 2020 | — | PT. Daewoong Infion | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEPIDERMIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108314 ↗ |
| Known as | EGF | “Epidermal growth factor (EGF) has been used as a booster for wound healing in the skin, and it has been suggested to have anti-pigmentation effects.” PMID 33668564 ↗ Feb 20214“urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis” NCT04886726 ↗ “we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs).” PMID 26041481 ↗ Jun 2015 “topical cream containing 1% silver sulfadiazine plus 6% epidermal growth factor (EGF)” NCT01553708 ↗ |
| Known as | EGF-genesis | “Epidermal growth factor "EGF-genesis" by Dermaquel Paris n into masseter and temporalis muscles.” NCT06044974 ↗ |
| Known as | epidermal growth factor | “urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis” NCT04886726 ↗8“epidermal growth factor (EGF) ointment” NCT02284139 ↗ |
| Known as | Nepidermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108314 ↗ |
| Known as | Nepidermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108314 ↗ |
| Known as | recombinant human Epidermal Growth Factor | “recombinant human epidermal growth factor (rhEGF) as a preventive drug of oral mucositis” NCT00845819 ↗ |
| Known as | rhEGF | “The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local...” NCT02554851 ↗9“EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)” NCT03047863 ↗ “EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF” NCT03051880 ↗ “recombinant human EGF (rhEGF)” NCT01593995 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human epidermal growth factor (rhEGF)” NCT00845819 ↗ |
| Route | Other | “spray type” NCT01099891 ↗ |